Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERAP2 | Q6P179 | 4/20 | 0.46 |
| ▸ | ERAP1 | Q9NZ08 | 4/20 | 0.46 |
| ▸ | LAP3 | P28838 | 3/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.46 |
| ▸ | ANPEP | P15144 | 2/20 | 0.46 |
| ▸ | IL1RN | P18510 | 2/20 | 0.46 |
| ▸ | CPA1 | P15085 | 1/20 | 0.44 |
| ▸ | CPA2 | P48052 | 1/20 | 0.44 |
| ▸ | CPA4 | Q9UI42 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4874778 | 0.85 | LAP3 (0.47) | ERAP2ERAP1LAP3FOLH1ANPEP | |
| SCHEMBL4865803 | 0.84 | TSHR (0.49) | ERAP2ERAP1LAP3FOLH1ANPEP | |
| SCHEMBL4870212 | 0.79 | FOLH1 (0.50) | FOLH1 | |
| SCHEMBL4869321 | 0.79 | FOLH1 (0.50) | FOLH1 | |
| SCHEMBL4872946 | 0.78 | GCLC (0.51) | FOLH1 | |
| SCHEMBL5053123 | 0.77 | FOLH1 (0.61) | FOLH1 | |
| SCHEMBL12145183 | 0.76 | GRM3 (0.68) | FOLH1CPA1CPA2CPA4 | |
| SCHEMBL1374848 | 0.75 | FOLH1 (0.59) | FOLH1 | |
| SCHEMBL1374317 | 0.74 | FOLH1 (0.57) | FOLH1 | |
| SCHEMBL6682065 | 0.73 | MMP1 (0.46) | FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7402576-B2 | Phosphinic acid analogs of glutamate | GIVAUDAN SA (CH) | 2008-07-22 | — | — | US | disclosed |
| US-7402576-B2 | Phosphinic acid analogs of glutamate | GIVAUDAN SA (CH) | 2008-07-22 | — | — | US | disclosed |
| US-7402576-B2 | Phosphinic acid analogs of glutamate | GIVAUDAN SA (CH) | 2008-07-22 | — | — | US | disclosed |
| EP-1599487-B1 | PHOSPHINIC ACID ANALOGS OF GLUTAMATE | GIVAUDAN SA (CH) | 2007-07-11 | — | — | EP | disclosed |
| EP-1599487-B1 | PHOSPHINIC ACID ANALOGS OF GLUTAMATE | GIVAUDAN SA (CH) | 2007-07-11 | — | — | EP | disclosed |
| US-20060052616-A1 | Phosphinic acid analogs of glutamate | GIVAUDAN SA (CH) | 2006-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052616-A1 | Phosphinic acid analogs of glutamate | GLUL, GRIA1, GRM1 | ERAP2 2679/4885ERAP1 2093/4885LAP3 3020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.